Translational neuropharmacology and the appropriate and effective use of animal models

British Journal of Pharmacology

Volumn 164, Issue 4, 2011, Pages 1041-1043

  Green, Ar ^a   Gabrielsson, J ^b   Fone, Kcf ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

animal models; clinical trials; neuropharmacology; pharmacokinetics; psychopharmacology; quantitative pharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL NERVOUS SYSTEM AGENTS; NEUROLEPTIC AGENT; NEW DRUG;

ANIMAL MODEL; CEREBROVASCULAR ACCIDENT; DRUG INFORMATION; DRUG LEGISLATION; DRUG RESEARCH; MEDICAL LITERATURE; MENTAL DISEASE; METHODOLOGY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROSCIENCE; NONHUMAN; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE STUDY; REPRODUCIBILITY; REVIEW; SYMPTOM;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPHARMACOLOGY; PHARMACOKINETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80053307134     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01361.x     Document Type: Review

References (19)

1. Bath PMW, Gray LJ, Bath AJG, Buchan AM, Miyata T, Green AR, (2009a). Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 157: 1157-1171.
2. Bath PMW, Macleod MR, Green AR, (2009b). Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke 4: 471-479.
3. Berge O-G, (2011). Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol 164: 1195-1206.
4. Constantinescu CS, Farooqi N, O'Brien K, Gran B, (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164: 1079-1106.
5. Cryan JF, Sweeney FF, (2011). The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol 164: 1129-1161.
6. Dirnagl U, Macleod MR, (2009). Stroke research at a roadblock: the streets from adversity should be paved with meta-analysis and good laboratory practice. Br J Pharmacol 157: 1154-1156.
7. Enna SJ, Williams M, (2009). Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther 329: 404-411.
8. Fineberg NA, Chamberlain SR, Hollander E, Boulougouris V, Robbins TW, (2011). Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment. Br J Pharmacol 164: 1044-1061.
9. Gabrielsson J, Green AR, (2009). Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331: 767-774.
10. Gabrielsson J, Green AR, Van der Graaf PH, (2010). Optimising in vivo pharmacology studies-practical PKPD considerations. J Pharmacol Toxicol Methods 61: 146-156.
11. Geyer MA, Markou A, (1995). Animal models of psychiatric disorders. In:, Bloom FE, Kupfer DJ, (eds). Psychopharmacology: the Fourth Generation of Progress. Raven Press: New York, pp. 787-798.
12. Geyer MA, Markou A, (2002). The role of preclinical models in the development of psychotropic drugs. In:, Davis KL, Coyle JT, Nemeroff C, (eds). Psychopharmacology: the Fifth Generation of Progress. Lipincott, Williams and Wilkins: Philadelphia, pp. 445-455.
13. Jones CA, Watson DJG, Fone KCF, (2011). Animal models of schizophrenia. Br J Pharmacol 164: 1162-1194.
14. Macrae IM, (2011). Preclinical stroke research-advantages and disadvantages of the common rodent models of focal ischaemia. Br J Pharmacol 164: 1062-1078.
15. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T, (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34: 74-89.
16. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE Guidelines. Br J Pharmacol 160: 1573-1576.
17. Spedding M, Jay T, Costa e Silva J, Perret L, (2005). A pathophysiological paradigm for the therapy of psychiatric disease. Nat Rev Drug Discov 4: 467-474.
18. Wickens JR, Hyland BI, Tripp G, (2011). Animal models to guide clinical drug development in ADHD: lost in translation? Br J Pharmacol 164: 1107-1128.
19. Willner P, (1984). The validity of animal models of depression. Psychopharmacology (Berl) 83: 1-16. (Pubitemid 14141479)